Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion

Table 3

Associations between mean doxorubicin cumulative dose and changes in LVEF and BNP.

Variables	Level	Cumulative dose
			Mean cumulative dose (mg/m^2)	Max dose (mg/m^2)	Median cumulative dose (mg/m^2)	value
LVEF drop from baseline to end of study	<10%	34	490	540	540	0.040
	>10%	4	435	525	428
BNP increase from baseline to end of study	<10%	21	521	540	540	0.551
	>10%	5	504	540	540